Eris Lifesciences Limited
NSE: ERIS · Pharmaceuticals · sector
₹1,105.20NSE close 2026-10-26
Key numbers
Market cap₹15,318 cr
Price₹1,105.20
52w high / low₹1,740 / ₹1,105
P/E23.5xSector median 27.9x
P/B3.9xSector median 2.9x
Book value₹281.6
Dividend yield–Sector median 0.48%
ROE19.1%Sector median 11.7%
ROCE13.7%Sector median 12.3%
OPM34.8%Sector median 14.0%
Debt / equity0.59xSector median 0.16x
EV/EBITDA15.7xSector median 18.6x
Interest cover4.5x
Current ratio0.74x
Sales growth 3y+22.9%Sector median +9.6%
Profit growth 3y+17.5%Sector median +13.3%
PEG1.36x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹67 cr vs borrowings ₹2,310 cr (FY26): borrowings are higher by ₹2,242 cr.
- Operating profit covered interest 4.5x in the last 12 months.
- 21.25% of the promoters' shares are pledged (11.6% of all shares).
- Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 1% of net profit in the last 12 months.
- Dividend paid in 3 of the last 5 financial years.
- Price ₹1,105.20 on 2026-10-26: -36.5% from the 52-week high, 0.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,808.10 · low ₹1,105.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 739 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| EBITDA | 262 | 250 | 252 | 277 | 288 | 264 | 274 | 296 |
| OPM % | 35.5% | 34.4% | 35.8% | 35.8% | 36.4% | 32.7% | 36.2% | 33.9% |
| Other income | 7 | 4 | 8 | 3 | 3 | 0 | 2 | 2 |
| Net profit | 92 | 84 | 94 | 118 | 120 | 100 | 282 | 142 |
| EPS (₹) | 6.73 | 6.15 | 6.90 | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 |
| Revenue YoY | +7.2% | +11.0% | +7.3% | +13.0% | ||||
| Profit YoY | +31.2% | +19.3% | +200.1% | +20.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 | 3,230 |
| EBITDA | 485 | 537 | 675 | 1,017 | 1,103 | 1,122 |
| Net profit | 406 | 382 | 392 | 352 | 620 | 644 |
| EPS (₹) | 29.89 | 28.10 | 28.82 | 25.85 | 45.33 | 47.02 |
| Revenue growth | +25.1% | +19.2% | +44.0% | +8.1% | +9.7% | |
| Profit growth | -5.9% | +2.6% | -10.2% | +76.1% | +66.4% | |
| Dividend / share (₹) | 6.01 | 7.35 | – | 7.35 | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +22.9% | +20.9% | +9.7% |
| Net profit | +17.5% | +11.8% | +66.4% |
| EPS | +17.3% | +11.6% | – |
| Share price | – | -7.5% (2y) | -28.3% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 2,196 | 2,586 | 2,854 | 3,903 |
| Borrowings | – | 830 | 2,735 | 2,478 | 2,310 |
| Cash & equivalents | – | 88 | 1,401 | 228 | 67 |
| Total assets | – | 3,667 | 7,049 | 7,033 | 7,366 |
| Fixed assets | – | 356 | 505 | 662 | 708 |
| Capital work in progress | – | 21 | 19 | 67 | 171 |
| Investments | – | 7 | 16 | 11 | 10 |
| Receivables | – | 293 | 422 | 459 | 680 |
| Inventory | – | 131 | 189 | 335 | 437 |
| Payables | – | 125 | 268 | 332 | 330 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 378 | 292 | 486 | 1,065 | 538 |
| Cash from investing | -320 | -975 | -1,828 | -80 | -369 |
| Cash from financing | -45 | 688 | 1,380 | -881 | -314 |
| Capex | 121 | 841 | 129 | 155 | 297 |
| Free cash flow | 257 | -550 | 357 | 910 | 241 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 17.4% | 15.2% | 12.3% | 15.9% |
| ROCE % | – | 14.2% | 9.7% | 13.5% | 13.4% |
| Debtor days | – | 63 | 77 | 58 | 79 |
| Inventory days | – | 136 | 182 | 171 | 200 |
| Payable days | – | 129 | 258 | 170 | 151 |
| Cash conversion cycle (days) | – | 70 | 1 | 59 | 128 |
| Working capital days | – | 70 | -42 | -15 | -63 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 54.74% |
| FIIs | 5.74% |
| DIIs | 20.20% |
| of which Mutual funds | 17.98% |
| of which Insurance | 1.53% |
| Government | 0.00% |
| Public (non-institutions) | 19.32% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 54.86% | 54.85% | 54.83% | 54.85% | 54.85% | 53.92% | 54.14% | 54.74% |
| Promoter group | % |
|---|---|
| Amit Indubhusan Bakshi | 42.96% |
| Rajendrakumar Rambhai Patel | 4.28% |
| Inderjeet Singh Negi | 4.28% |
| Kaushal Kamleshkumar Shah | 3.22% |
| Sarthak Negi | 0.00% |
| Suman Negi | 0.00% |
| Sateshwari Devi | 0.00% |
| Rajeshwari Negi | 0.00% |
| Rekha Rawat | 0.00% |
| Asha Rawat | 0.00% |
| Manvendra Singh Negi | 0.00% |
| Aditi Negi | 0.00% |
| Shiv Chanran Singh Rawat | 0.00% |
| Rameshwari Devi Rawat | 0.00% |
| Sandeepa Rawat | 0.00% |
| Public holders above 1% | % |
|---|---|
| Lilac Investments Limited | 8.62% |
| Hdfc Small Cap Fund | 8.19% |
| Franklin India Small Cap Fund | 3.76% |
| Hetal Rasiklal Shah | 2.12% |
| Bhikhalal Chimanlal Shah | 1.93% |
| Naishadh Vikram Shah | 1.66% |
| Rakesh Shah | 1.42% |
| Uti-Flexi Cap Fund | 1.06% |
| Dsp Small Cap Fund | 1.05% |
| Hsbc Mutual Fund - Hsbc Small Cap Fund | 1.03% |
49,034 shareholders. Pledged: 21.25% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ERIS | ₹15,318 cr | 23.5x | 3.9x | 19.1% | 13.7% | 34.8% | +22.9% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-05-29 | Dividend | Interim Dividend - Rs 7.21 Per Share |
| 2025-02-13 | Dividend | Interim Dividend - Rs 7.35 Per Share |
| 2024-09-17 | Other | Annual General Meeting |
| 2023-09-15 | Other | Annual General Meeting |
| 2022-08-23 | Other | Annual General Meeting |
| 2022-08-11 | Dividend | Interim Dividend- Rs 7.35 Per Share |
| 2021-08-23 | Other | Annual General Meeting |
| 2021-08-05 | Dividend | Interim Dividend - Rs 6.01 Per Share |
| 2020-09-18 | Other | Annual General Meeting |
| 2020-08-13 | Dividend | Interim Dividend - Rs 5.50 Per Share |
| 2020-03-19 | Dividend | Interim Dividend - Rs 2.87 Per Share |
| 2019-09-18 | Other | Annual General Meeting |
| 2019-07-12 | Buyback | Buyback |
| 2018-09-19 | Other | Annual General Meeting |
| 2017-09-20 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceutical: Manufacturing and Marketing of Pharmaceutical Products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ERIS |
| BSE code | 540596 |
| ISIN | INE406M01024 |
| Face value | ₹1.0 |
| Incorporated | 2007-01-25 |
| Website | https://eris.co.in |
| Plants (India / abroad) | 1 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.